Cambium Bio has secured a A$3 million capital raise and achieved FDA Fast Track status for its lead ophthalmology product, Elate Ocular®, setting the stage for Phase 3 trials in mid-2025.
Nova Eye Medical reports a robust 39% increase in global sales driven by strong U.S. market demand and secures $6.6 million in fresh capital to fuel expansion and product development.
